Baseline Platelet-to-Lymphocyte Ratio in DLBCL CAR T-Cell Therapy Patients

A retrospective study of 15 patients with relapsed or refractory diffuse large B-cell lymphoma treated with tisagenlecleucel. It analyzes the association between baseline platelet-to-lymphocyte ratio and severe immune effector cell-associated toxicities, identifying an optimal PLR cutoff of 198 for prediction.

Use Cases

• Assess the predictive power of the baseline platelet-to-lymphocyte ratio for severe cytokine release syndrome and neurotoxicity in CAR T-cell therapy patients.
• Correlate baseline PLR values with post-infusion serum ferritin levels as a marker of systemic inflammation.
• Compare the sensitivity and specificity of PLR against other inflammatory biomarkers for toxicity risk stratification.

Strengths

• Defines a specific PLR cutoff of 198 with reported sensitivity of 85.7% and specificity of 87.5%.
• Provides a clear clinical context focusing on a specific patient cohort (15 DLBCL patients) and therapy (tisagenlecleucel).
• Data is associated with a published research methodology, including ROC analysis.

Limitations

• Very small sample size of 15 patients limits statistical power and generalizability of findings.
• Retrospective, single-study design introduces potential for bias; validation in larger cohorts is noted as needed.
• Dataset is extremely small (35.5 KB), indicating limited raw data, likely a summary table from the research paper.

Provenance

Source

figshare, authored by Changgon Kim.

Collection Method

Retrospective analysis of patient records.

Freshness

Last updated March 24, 2026.